Potential biological factors affecting the efficacy of immunotherapy for triple-negative breast cancer
10.3781/j.issn.1000-7431.2023.2207-0582
- VernacularTitle:影响三阴性乳腺癌免疫检查点抑制剂疗效的潜在生物学因素
- Author:
Xiaomei ZHOU
1
;
Bo LUO
Author Information
1. 华中科技大学同济医学院附属湖北肿瘤医院腹部放疗科,湖北 武汉 430079
- Keywords:
Triple-negative breast cancer(TNBC);
Immunotherapy;
Tumor microenvironments(TME);
Biologic factors;
Immune checkpoint inhibitors(ICIs)
- From:
Tumor
2023;43(2):143-150
- CountryChina
- Language:Chinese
-
Abstract:
Triple-negative breast cancer(TNBC)is characterized by strong aggressiveness,high metastatic potential,easy recurrence and poor prognosis.Due to lack of expression for estrogen receptor(ER),progesterone receptor(PR)and human epidermal growth factor(HER2)in TNBC patients,there is a lack of specific therapeutic targets and effective treatment plans for TNBC.At present,immunotherapy has been widely used in solid tumors.Immune checkpoint inhibitors(ICIs)have shown some preliminary clinical effects in the treatment of TNBC,but there were still some patients who do not respond to ICIs therapy or develop resistance,and multiple clinical studies cannot obtain consistent results on the efficacy of ICIs.Therefore,,we reviewed the potential biological factors that influence the efficacy of ICIs in TNBC,aiming to explore the mechanisms affecting the efficacy of ICIs and analyze its potential clinical value.
